Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02264613 · ClinicalTrials.gov registry record · Phase 1
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
A Phase 1 study, sponsored by Aileron Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 142
- Enrollment target
NCT02264613: Completed Phase 1 study, sponsored by Aileron Therapeutics.
NCT02264613 is a Phase 1 study that has completed, run by Aileron Therapeutics. The registered enrollment target is 142 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (137% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02264613, a Phase 1 study, has completed, sponsored by Aileron Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 142 participants
- Enrollment target
Study Summary
This study evaluates the anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with WT TP53.
Primary Outcome
Number of participants with treatment-related adverse events as assessed by CTCAE v.4.0
Interventions
- DRUG ALRN-6924
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2014-10 |
| Est. Completion | 2020-04 |
| Phase | Phase 1 |
What the finished NCT02264613 record still lists
NCT02264613 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (137% higher).
The record links to 0 conditions, and to 1 intervention - of which ALRN-6924 is the first listed.
NCT02264613 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02264613 about?
NCT02264613 is a clinical study titled "ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas". This study evaluates the anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with WT TP53.
What is the current status of trial NCT02264613?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 142 participants. The study started on 2014-10. Estimated completion is 2020-04.
What interventions are being tested in trial NCT02264613?
The interventions under investigation include: ALRN-6924 (DRUG).
Who is sponsoring clinical trial NCT02264613?
This trial is sponsored by Aileron Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02264613's enrollment target sits among peer trials
142 401st of 2000 higher than 1,600 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia